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Abstract. Genetic factors play an important role in the pathogenesis of schizophrenia. Dysregulations in the dopaminergic system have long
been known to play an influential role in the development of this disorder. Although a large number of studies have investigated the association
between genetic polymorphisms in the genes involved in this system and the risk of schizophrenia, the results have been inconsistent. In this
meta-analysis, we searched for publications in Ovid Medline, Embase, Web of Science (science citation index expanded), and PsycNET for
articles published until January 2020. We identified case–control studies investigating the association between four common genetic poly-
morphisms (rs6277, rs1799732, rs1800497, and rs1801028) and the risk of schizophrenia. The studies were subsequently selected according to
the predefined inclusion and exclusion criteria. The data extraction was conducted according to the PRISMA guidelines. We also assessed the
quality of the studies and investigated publication bias using funnel plot and Egger’s regression test. The association analysis was conducted in
allelic, dominant, and recessive genetic models. Subsequently, bioinformatics analysis of the effect of the polymorphisms found to be
significantly associated with schizophrenia on protein stability, posttranslational modifications, and 3D protein structure was conducted. This
meta-analysis showed that Taq1A (allelic model: OR, 0.856, 95% CI, 0.734–0.998) has a protective effect against the development of
schizophrenia. Further, itwas found that this variantmay decreaseANKK1protein stability. Further, this polymorphismwas found to lead to the
gain ofmodifications sites for ubiquitination (Ubi. score =-1.894) andmethylation (Meth. score =-0.834). Several genetic factors contribute
to the susceptibility of schizophrenia. The updated knowledge emerging from this meta-analysis showing the protective effect of rs1800497
polymorphism (Taq1A) can shed light on the role of Taq1A polymorphism in the susceptibility to schizophrenia and also pave way for further
functional studies investigating the role of ANKK1 protein in the pathogenesis of schizophrenia.
Keywords. schizophrenia; polymorphism; single nucleotide; genetic variation; meta-analysis.
Introduction
Schizophrenia is a common psychiatric disorder with an
average lifetime prevalence of about 1% (Kahn et al. 2015).
As pointed out by a plethora of investigations (e.g. twin
studies), this disorder is highly heritable (Cardno and
Gottesman 2000). Notwithstanding the elusive aetiologic
basis of this disorder, for quite some time, dysregulations in
dopaminergic neurotransmission have been hypothesized to
have an instrumental role in the pathogenesis of
schizophrenia (van Rossum 1966). One of the most studied
markers for the development of schizophrenia has been theParham Habibzadeh and Azim Nemati contributed equally to this work.
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DRD2 gene, located on chromosome 11q22.2, coding for
dopamine receptor D2 (Seeman 1987). Further, the elevated
striatal DRD2 density has been demonstrated in patients with
schizophrenia (Abi-Dargham et al. 2000). The association of
DRD2, the target of all affective antipsychotic medications,
with schizophrenia has also been corroborated by a
Table 1. Characteristics of the studied SNPs (data extracted from the NCBI database).
SNP Chromosome (GRCh38) Chromosome (GRCh37) Canonical SPDI
rs6277 11:113412737 11:113283459 NC_000011.10:113412736:G:A
rs1799732 11:113475529 11:113346252 NC_000011.10:113475529:G:GG
rs1800497 11:113400106 11:113270828 NC_000011.10:113400105:G:A
rs1801028 11:113412762 11:113283484 NC_000011.10:113412761:G:C
SDPI, sequence position deletion insertion.
Figure 1. Flowchart of the study identification process.
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genomewide association study, identifying DRD2 as one of
the major risk genes for schizophrenia (Beaulieu and
Gainetdinov 2011; Schizophrenia Working Group of the
Psychiatric Genomics 2014). Ankyrin repeat and kinase
domain containing 1 (ANKK1) is another gene that is closely
associated with DRD2 and is closely related to dopaminergic
signalling (Koeneke et al. 2020). Taq1A, a polymorphism
originally associated with DRD2 has recently been found to
be located on the ANKK1 gene (Neville et al. 2004).
Association between schizophrenia and the four common
single-nucleotide polymorphisms, namely rs6277,
rs1799732, rs1800497 and rs1801028 (table 1), which are
associated with DRD2 has been extensively studied (Dollfus
et al. 1996; Breen et al. 1999; Jonsson et al. 2003). Unfortu-
nately, due to different genetic backgrounds, potential con-
founding bias, and small sample size, the results of these
investigations have been either conflicting or inconsistent. A
meta-analysis including 10 case–control studies conducted by
Glatt et. al. in 2004 to assess the potential association between
rs1799732 polymorphism and schizophrenia failed to show
any associations (Glatt et al. 2004). Other meta-analyses have
also been performed in recent years to evaluate the association
between DRD2 polymorphisms and schizophrenia with
inconsistent results (Glatt and Jonsson 2006; Watanabe et al.
2015; Yao et al. 2015; Wang et al. 2016). New genetic asso-
ciation studies which have not been included in these meta-
analyses have been recently conducted to shed light on the
association between different DRD2 polymorphisms and
schizophrenia (Kaur et al. 2019b; Zhang et al. 2019a). We
have conducted thismeta-analysis to provide a comprehensive
assessment of the association between four common genetic
polymorphism and schizophrenia.
Materials and methods
Search strategy and selection criteria
Potentially relevant literature published before January 2020
were retrieved from Ovid Medline, Embase, Web of Science
(science citation index expanded), and PsycNET using the
combination of following terms: (‘DRD2’ OR ‘Dopamine
receptor 2’ OR ‘Dopamine receptor D2’ OR ‘Dopamine D2
receptor’) AND (‘SNP’ OR ‘polymorphism’ OR ‘variant’
OR ‘genotype’ OR ‘allele’) AND (‘Schizophrenia’). The
reference lists of all retrieved articles were also reviewed for
other eligible articles. The search strategy was not confined
to any language or time period.
Studies were considered eligible to test the research
hypothesis of this meta-analysis if they met the following
criteria: (i) case–control studies investigating the association
between the mentioned polymorphisms (rs6277, rs1799732,
rs1800497, and rs1801028) and schizophrenia; (ii) provide
adequate data on genotype and/or allelic frequency of the
studied variants in both cases (i.e., patients diagnosed with
schizophrenia) and controls to calculate the odds ratio (OR)
and 95% confidence interval (CI). Studies were excluded in
case of one of the following conditions (i) not relevant to the
mentioned genetic variants and schizophrenia; (ii) case
reports and case series; (iii) book chapters, reviews, con-
ference abstracts, comments, letters to the editor, animal
studies and studies lacking a control group. In the case of
repeated inclusion of subjects in more than one publication,
we only included the study with the largest sample size.
Data extraction and quality assessment
Two investigators (AN and AT) independently reviewed all
abstracts to evaluate the appropriateness of the articles and the
eligibility criteria. Disagreements were resolved by a con-
sensus and discussion with a third investigator (PH). The
following information was extracted from the eligible studies:
the first author’s name, year of publication, country of origin,
the ethnicity of the studied population, gender (male per-
centage), source of control population, mean age of cases and
controls, diagnostic criteria, number of genotyped cases and
controls, genotype/allele frequency for cases and controls.
Study authors were contacted to identify further study and also
the missing information. Newcastle–Ottawa scale (NOS) was
used to assess the methodological quality of the included
Table 3. rs6277 genotype and allele frequency distribution.
Reference
Cases (n) Controls (n) Cases (%) Controls (%) PHWE
C/C C/T T/T C/C C/T T/T C T C T Cases Control
Lawford et al. (2005) 48 75 31 27 70 51 55.51948 44.48052 41.89189189 58.10810811 0.862481 0.728738
Hanninen et al. (2006) 59 92 37 104 176 104 55.85106 44.14894 50 50 0.91605 0.10247
Hoenicka et al. (2006) 30 61 40 46 174 144 46.18321 53.81679 36.53846154 63.46153846 0.469154 0.557312
Kukreti et al. (2006) 41 38 22 48 64 33 59.40594 40.59406 55.17241379 44.82758621 0.027094 0.194704
Monakhov et al. (2008) 99 152 60 78 183 103 56.2701 43.7299 46.56593407 53.43406593 0.903279 0.844807
Betcheva et al. (2009) 58 128 66 192 253 111 48.4127 51.5873 57.28417266 42.71582734 0.788511 0.097893
Gupta et al. (2009) 104 112 38 76 120 29 62.99213 37.00787 60.44444444 39.55555556 0.38721 0.083629
Fan et al. (2010) 366 52 3 368 34 1 93.11164 6.888361 95.53349876 4.466501241 0.446254 0.818987
Tsutsumi et al. (2011) 367 38 1 341 43 2 80.51471 19.48529 86.63366337 13.36633663 0.070923 0.340652
Han et al. (2017) 554 109 27 410 13 7 88.18841 11.81159 96.86046512 3.139534884 2.16E-10 1.84E-25
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studies (Stang 2010). Only studies with moderate or high
methodological quality were included in the meta-analysis.
Statistical analysis
Chi-square goodness of fit test was used to determine devia-
tion from Hardy–Weinberg equilibrium (HWE) in the studied
populations. Cochran’s Q test and the I2 statistics were used to
assess heterogeneity among included studies (Huedo-Medina
et al. 2006). In case of I2 values[50% or Q statistic P-value\
0.1, random-effects model (Dersimonian-Laird method) was
used. Otherwise, fixed-effects model was applied.
PooledORswith 95%CIs adopting dominant, recessive, and
allelic models were used to estimate the strength of association
between the genetic polymorphisms and schizophrenia. Sub-
group analysis by ethnicity (Caucasian andEastAsian)was also
performed in the allelicmodel. Publication biaswas assessed by
visual inspection of the funnel plot and Egger’s regression test
(Begg and Mazumdar 1994; Egger et al. 1997). Statistical
analysis was conducted using metaphor package in R software
(v. 3.6.3) (see methods in electronic supplementary material at
http://www.ias.ac.in/jgenet/) (Viechtbauer 2010).
Bioinformatics analysis
The effect of genetic polymorphisms found to be signifi-
cantly associated with schizophrenia on protein stability was
evaluated using the I-Mutant Suite tool (http://gpcr2.
biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi).
Further, their effects on posttranslational modifications were
investigated using AWESOME (http://www.awesome-hust.
com) (Yang et al. 2019). The effect of SNP on protein
structure was visualized using HOPE (https://www3.cmbi.
umcn.nl/hope/) (Venselaar et al. 2010). Further, the 3D pro-
tein structure modelling was conducted using SWISSMODEL
(https://swissmodel.expasy.org/) and energy minimization was
carried out using SPDBV. Subsequently root-mean-square
deviation (RMSD) value was calculated by PyMOL to eval-
uate the structural change in the protein as a result of the
variant.
This meta-analysis was conducted in adherence to the
preferred reporting items for systematic reviews and meta-
analyses (PRISMA) guideline (Liberati et al. 2009).
Results
Study characteristics
The flow diagram depicting the study selection process is
shown in figure 1. A total of 633 articles were initially
identified through database search. This number was reduced
to 498 after the removal of duplicates. Further, after
assessing the articles based on the inclusion and exclusion
criteria, 75 studies were found to be eligible (Comings et al.
1991; Itokawa et al. 1993; Sanders et al. 1993; Arinami
Table 4. rs1799732 genotype and allele frequency distribution.
References
Cases (n) Controls (n) Cases (%) Controls (%) PHWE
Ins/Ins Ins/Del Del/Del Ins/Ins Ins/Del Del/Del Ins Del Ins Del Cases Control
Arinami et al. (1997) 190 66 4 193 102 17 85.76923 14.23077 78.20513 21.79487 0.520258 0.469118
Li et al. (1998) 112 39 0 118 26 1 87.08609 12.91391 90.34483 9.655172 0.068424 0.737736
Ohera et al. (1998) 136 34 0 84 36 1 90 10 84.29752 15.70248 0.147418 0.173126
Stober et al. (1998) 207 50 3 236 53 1 89.23077 10.76923 90.51724 9.482759 0.992078 0.271373
Breen et al. (1999) 318 111 10 345 87 5 85.07973 14.92027 88.9016 11.0984 0.931919 0.852793
Inada et al. (1999) 156 72 6 51 40 3 82.05128 17.94872 75.53191 24.46809 0.494667 0.142519
Tallerico et al. (1999) 40 10 0 43 7 1 90 10 91.17647 8.823529 0.432058 0.293968
Jonsson et al. (1999) 114 15 0 142 34 3 94.18605 5.813953 88.82682 11.17318 0.483241 0.564348
Hori et al. (2001) 162 71 8 142 54 5 81.95021 18.04979 84.0796 15.9204 0.948493 0.960274
Himei et al. (2002) 118 69 3 71 27 5 80.26316 19.73684 82.03883 17.96117 0.043838 0.262065
Kampman et al. (2003) 86 7 0 88 6 0 96.23656 3.763441 96.80851 3.191489 0.70608 0.749251
Dubertret et al. (2004) 83 19 1 43 33 7 89.80583 10.19417 71.68675 28.31325 0.939612 0.851407
Parsons et al. (2007) 88 20 0 135 18 0 90.74074 9.259259 94.11765 5.882353 0.288945 0.439474
Lafuente et al. (2008) 208 33 2 235 54 2 92.38683 7.613169 90.03436 9.965636 0.589515 0.560906
Sanders et al. (2008) 1495 354 21 1643 341 18 89.41176 10.58824 90.58442 9.415584 0.993121 0.947429
Luu et al. (2008) 165 44 2 163 34 4 88.62559 11.37441 89.55224 10.44776 0.618177 0.17336
Cordeiro et al. (2009) 183 38 8 498 206 29 88.20961 11.79039 81.99181 18.00819 0.00221 0.190838
Gupta et al. (2009) 205 44 3 169 50 4 90.07937 9.920635 86.99552 13.00448 0.714035 0.892319
Srivastava et al. (2009) 161 65 7 172 48 4 83.04721 16.95279 87.5 12.5 0.887637 0.76003
Dubertret et al. (2010) 104 37 3 120 21 1 85.06944 14.93056 91.90141 8.098592 0.890378 0.938291
Saiz et al. (2010) 181 76 15 301 98 5 80.51471 19.48529 86.63366 13.36634 0.070923 0.340652
Kurt et al. (2010) 45 26 2 34 25 1 79.45205 20.54795 77.5 22.5 0.437847 0.131433
Xiao et al. (2013) 96 22 2 68 28 4 89.16667 10.83333 82 18 0.576065 0.606619
Zhang et al. (2014) 257 34 15 275 44 5 89.54248 10.45752 91.66667 8.333333 1.12E-12 0.0455
Funahashi et al. (2019) 74 25 1 69 29 2 86.5 13.5 83.5 16.5 0.481217 0.599996
Nunes et al. (2019) 9 36 99 9 23 40 18.75 81.25 28.47222 71.52778 0.031252 0.067179
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et al. 1994; Asherson et al. 1994; Campion et al. 1994;
Gejman et al. 1994; Hattori et al. 1994; Laurent et al. 1994;
Nanko et al. 1994; Nothen et al. 1994; Shaikh et al.
1994; Sobell et al. 1994; Arinami et al. 1996; Chen et al.
1996; Crawford et al. 1996; Dollfus et al. 1996; Jonsson
et al. 1996; Ohara et al. 1996; Sasaki et al. 1996; Tanaka
et al. 1996; Arinami et al. 1997; Fujiwara et al. 1997;
Harano 1997; Kaneshima et al. 1997; Verga et al. 1997;
Li et al. 1998; Ohara et al. 1998; Spurlock et al. 1998;
Stober et al. 1998; Breen et al. 1999; Inada et al. 1999;
Jonsson et al. 1999; Tallerico et al. 1999; Serretti et al. 2000;
Dubertret et al. 2001, 2004, 2010; Hori et al. 2001; Himei
et al. 2002; Morimoto et al. 2002; Jonsson et al. 2003;
Kampman et al. 2003; Lawford et al. 2005; Hanninen et al.
2006; Hoenicka et al. 2006; Kukreti et al. 2006; Parsons
et al. 2007; Vijayan et al. 2007; Lafuente et al. 2008;
Behravan et al. 2008; Luu et al. 2008; Monakhov et al.
2008; Sanders et al. 2008; Betcheva et al. 2009; Cordeiro
et al. 2009; Gupta et al. 2009; Fan et al. 2010; Saiz et al.
2010; Srivastava et al. 2010; Kurt et al. 2011; Tsutsumi et al.
2011; Watanabe et al. 2012; Xiao et al. 2013; Alfimova et al.
2014; Cordeiro and Vallada 2014; Zhang et al. 2014; Arab
and Elhawary 2015; Han et al. 2017; Alfimova et al. 2019;
Funahashi et al. 2019; Kaur et al. 2019a; Nunes 2019;
Poorshekar et al. 2019; Zhang et al. 2019b). However, after
further investigations, six articles were not included in the
meta-analysis due to the overlap of their studied populations
with other published studies (Itokawa et al. 1993; Arinami
et al. 1994; Nanko et al. 1994; Tanaka et al. 1996; Verga
et al. 1997; Alfimova et al. 2014). The data for rs1801028
SNP presented in a study by Himei et al. (2002) was not
included in the meta-analysis for this variant since it was
already included in an investigation conducted by Tsutsumi
et al. (2011). Further, one study was excluded because of
low NOS score (Shaikh et al. 1994). At the end, 68 studies
with 15,200 cases and 18,111 controls investigating the
association of four genetic polymorphisms and schizophre-
nia were included in the meta-analysis. There were 31
studies with 8639 cases and 9743 controls investigated the
association between rs1801028 and schizophrenia. The
relationship between rs1800497 and schizophrenia was
assessed in 20 studies involving 3416 cases and 3780 con-
trols. For rs1799732 polymorphism, 26 studies with 6625
cases and 7139 controls were carried out to elucidate the
relationship between this variant and schizophrenia. Ten
studies involving 2908 cases and 3405 controls investigated
the correlation between rs6277 variant and schizophrenia.
Overall, the included studies represented different popula-
tions, namely Caucasian, East Asian, Indian, African Arab
and mixed. The characteristics of the included studies are
displayed in table 2. The distribution of the genotypes and
allele frequencies for the studied SNPs across the included
studies are demonstrated in tables 3–6.
Quantitative synthesis
Analysis of association between rs6277 and schizophrenia: No
significant association was observed between this polymor-
phism and schizophrenia under the studied genetic models:
allelic model (OR, 0.998, 95% CI, 0.737–1.352), dominant
model (OR, 1.131, 95% CI, 0.824–1.552), and recessive
Table 5. rs1800497 genotype and allele frequency distribution.
References
Cases (n) Controls (n) Cases (%) Controls (%) PHWE
C/C C/T T/T C/C C/T T/T C T C T Cases Control
Comings et al. (1991) 58 27 2 59 10 0 82.18391 17.81609 92.75362 7.246377 0.577131 0.516367
Sanders et al. (1993) 38 16 1 36 12 3 83.63636 16.36364 82.35294 17.64706 0.641393 0.173744
Campion et al. (1994) 60 19 1 58 20 2 86.875 13.125 85 15 0.710814 0.860783
Dollfus et al. (1996) 41 19 2 111 45 5 81.45161 18.54839 82.91925 17.08075 0.910937 0.866198
Jonsson et al. (1996) 70 30 4 45 18 4 81.73077 18.26923 80.59701 19.40299 0.728365 0.248359
Dubertret et al. (2001) 36 13 1 26 21 3 85 15 73 27 0.889728 0.643512
Dubertret et al. (2004) 71 29 3 30 40 13 83.00971 16.99029 60.24096 39.75904 0.985118 0.955967
Parsons et al. (2007) 92 24 3 93 68 4 87.39496 12.60504 76.9697 23.0303 0.355984 0.036911
Vijayan et al. (2007) 102 93 17 88 77 29 70.04717 29.95283 65.20619 34.79381 0.508453 0.080989
Behravan et al. (2008) 11 21 6 21 39 3 56.57895 43.42105 64.28571 35.71429 0.441939 0.005721
Lafuente et al. (2008) 157 81 5 184 90 13 81.27572 18.72428 79.79094 20.20906 0.137914 0.639709
Monakhov et al. (2008) 189 104 18 238 116 10 77.49196 22.50804 81.31868 18.68132 0.465598 0.350971
Srivastava et al. (2009) 123 93 17 107 96 21 72.74678 27.25322 69.19643 30.80357 0.919514 0.936423
Dubertretet al. (2010) 94 44 6 79 54 9 80.55556 19.44444 74.64789 25.35211 0.767561 0.955175
Cordeiro et al. (2014) 94 112 29 289 407 138 63.82979 36.17021 59.05276 40.94724 0.622044 0.792741
Zhang et al. (2014) 150 181 65 161 187 51 60.73232 39.26768 63.78446 36.21554 0.406561 0.772921
Arab et al. (2015) 77 43 0 55 33 12 82.08333 17.91667 71.5 28.5 0.016799 0.057062
Alfimova et al. (2019) 148 79 10 150 64 11 79.11392 20.88608 80.88889 19.11111 0.894106 0.230199
Kaur et al. (2019a, b) 202 205 36 63 72 15 68.73589 31.26411 66 34 0.106499 0.394532
Nunes et al. (2019) 75 61 8 35 29 8 73.26389 26.73611 68.75 31.25 0.329219 0.595141
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model (OR, 1.036, 95% CI, 0.681–1.575) (figure 2; table 7).
Further, subgroup analysis in East Asian (OR, 0.575, 95%
CI, 0.225–1.470) and Caucasian populations (OR, 1.265,
95% CI, 0.904–1.770) showed no significant associations.
Analysis of the association between rs1799732 and schizophre-
nia: Summary results of the meta-analysis showed no sig-
nificant association between rs1799732 and schizophrenia
under allelic (OR, 0.966, 95% CI, 0.822–1.135), dominant
(OR, 0.952, 95% CI, 0.800–1.133), and recessive models
(OR, 1.060, 95% CI, 0.744–1.511) (figure 3; table 7). In
addition, subgroup analysis in East Asian (OR, 0.845, 95%
CI, 0.672–1.062) and Caucasian populations (OR, 1.060,
95% CI, 0.837–1.342) demonstrated no significant
associations.
Analysis of association between rs1800497 and schizophrenia:
The pooled results showed that rs1800497 polymorphism
was significantly associated with schizophrenia in the stud-
ied populations under the allelic genetic model (OR, 0.856,
95% CI, 0.734–0.998) (figure 4). However, no significant
associations were observed under other genetic models:
dominant model (OR, 0.861, 95% CI, 0.723–1.026), and
recessive model (OR, 0.755, 95% CI, 0.555–1.025) (fig-
ure 4; table 7). Subgroup analysis in East Asian (OR, 1.139,
95% CI, 0.930–1.395) and Caucasian populations (OR,
0.873, 95% CI, 0.671–1.135).
Analysis of the association between rs1801028 and schizophre-
nia: This meta-analysis failed to find any significant asso-
ciations between rs1801028 and schizophrenia under
different genetic models: allelic model (OR, 1.009, 95% CI,
0.893–1.140), dominant model (OR, 1.020, 95% CI,
0.897–1.160), and recessive model (OR, 0.994, 95%
CI, 0.402–2.456) (figure 5; table 7). The subgroup analysis
in East Asian (OR, 0.995, 95% CI, 0.824–1.201) and
Caucasian populations (OR, 1.292, 95% CI, 0.906–1.842)
was also unable to detect any significant associations.
Evaluation of heterogeneity and publication bias
There was significant heterogeneity across the included
studies for rs6277, rs1799732, and rs1800497 under all
Table 6. rs1801028 genotype and allele frequency distribution.
References
Cases (n) Controls (n) Cases (%) Controls (%) PHWE
C/C C/G G/G C/C C/G G/G C G C G Cases Control
Gejman et al. (1994) 103 3 0 109 4 0 98.58491 1.415094 98.23009 1.769912 0.882513 0.848107
Asherson et al. (1994) 110 2 0 63 1 0 99.10714 0.892857 99.21875 0.78125 0.924043 0.949773
Nothen et al. (1994) 175 4 0 133 5 0 98.88268 1.117318 98.18841 1.811594 0.879837 0.828411
Hattori et al. (1994) 93 7 0 93 6 1 96.5 3.5 96 4 0.716833 0.028706
Laurent et al. (1994) 108 8 0 181 3 0 96.55172 3.448276 99.18478 0.815217 0.700493 0.911228
Sobell et al. (1994) 326 12 0 1848 65 1 98.22485 1.775148 98.24974 1.750261 0.739697 0.582425
Arinami et al. (1996) 124 12 0 265 14 0 95.58824 4.411765 97.49104 2.508961 0.59041 0.667294
Chen et al. (1996) 110 4 0 83 5 0 98.24561 1.754386 97.15909 2.840909 0.84879 0.783859
Crawford et al. (1996) 78 5 1 78 3 0 95.83333 4.166667 98.14815 1.851852 0.019597 0.865159
Ohara et al. (1996) 152 1 0 118 3 0 99.6732 0.326797 98.76033 1.239669 0.967651 0.890181
Sasaki et al. (1996) 261 12 0 245 9 1 97.8022 2.197802 97.84314 2.156863 0.710416 0.008913
Harano et al. (1997) 62 8 0 93 8 0 94.28571 5.714286 96.0396 3.960396 0.612108 0.678561
Fujiwara et al. (1997) 50 2 0 25 1 0 98.07692 1.923077 98.07692 1.923077 0.887559 0.92036
Kaneshima et al. (1997) 74 4 0 105 7 0 97.4359 2.564103 96.875 3.125 0.816216 0.732812
Spurlock et al. (1998) 359 14 0 396 17 0 98.12332 1.876676 97.94189 2.058111 0.711846 0.669345
Serretti et al. (2000) 329 37 0 252 15 0 94.94536 5.054645 97.19101 2.808989 0.308444 0.636742
Hori et al. (2001) 217 23 1 185 15 1 94.81328 5.186722 95.77114 4.228856 0.645064 0.264608
Morimoto et al. (2002) 42 6 0 42 6 0 93.75 6.25 93.75 6.25 0.644167 0.644167
Jonsson et al. (2003) 160 12 1 232 4 0 95.95376 4.046243 99.15254 0.847458 0.160443 0.895537
Dubertret et al. (2004) 97 6 0 80 3 0 97.08738 2.912621 98.19277 1.807229 0.760772 0.866838
Vijayan et al. (2007) 169 38 3 159 32 4 89.52381 10.47619 89.74359 10.25641 0.608971 0.12949
Sanders et al. (2008) 1796 73 1 1895 105 2 97.99465 2.005348 97.27772 2.722278 0.770417 0.662992
Gupta et al. (2009) 208 42 4 186 37 2 90.15748 9.84252 90.88889 9.111111 0.276386 0.915228
Srivastava et al. (2009) 200 32 1 189 34 1 92.70386 7.296137 91.96429 8.035714 0.815925 0.686484
Dubertret et al. (2010) 139 5 0 137 5 0 98.26389 1.736111 98.23944 1.760563 0.832096 0.830894
Fan et al. (2010) 387 32 1 377 26 0 95.95238 4.047619 96.77419 3.225806 0.695154 0.503392
Tsutsumi et al. (2011) 390 14 8 354 23 7 96.35922 3.640777 95.18229 4.817708 1.22E-25 1.06E-11
Watanabe et al. (2012) 607 40 1 617 46 1 96.75926 3.240741 96.38554 3.614458 0.689013 0.882635
Han et al. (2017) 632 51 7 396 26 8 95.28986 4.710145 95.11628 4.883721 3.5E-06 4.47E-13
Kaur et al. (2019a, b) 443 0 0 150 0 0 100 0 100 0 NA NA
Poorshekar et al. (2019) 96 4 0 100 0 0 98 2 100 0 0.83829 NA















































































































































































































































































































































































































































































































































































Figure 2. Forest plot of the risk of schizophrenia associated with
rs6277 under (a) allelic, (b) dominant, and (c) recessive genetic
models.
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Figure 3. Forest plot of the risk of schizophrenia associated with
rs1799732 under (a) allelic, (b) dominant, and (c) recessive genetic
models.
Figure 4. Forest plot of the risk of schizophrenia associated with
rs1800497 under (a) allelic, (b) dominant, and (c) recessive genetic
models.
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studied genetic models. However, the included studies on
rs1801028 did not show significant heterogeneity under all
studied genetic models. Further, there was no evidence of
publication bias according to Egger’s regression test results
(table 7). Funnel plots are also presented in figures 1–4 in
electronic supplementary material.
Bioinformatics analysis
Analysis of the effect of rs1800497 on ANKK1 protein
revealed that the substitution of glutamic acid by lysine
caused by this mutation may decrease protein stability.
Further, this polymorphism was found to lead to the gain of
modifications sites for ubiquitination (ubi. score = -1.894)
and methylation (meth. score = -0.834). The 3-D protein
structure analysis of ANKK1 protein and the effects of this
SNP on protein structure were also visualized (figure 6). The
minimized total energy of wild type and mutant proteins
were -20145.709 kcal/mol and -20125.746 kcal/mol,
respectively. Further, the RMSD value was 0.008Å.
Discussion
Schizophrenia is a common psychiatric disorder occurring
throughout the globe presenting with chronic or recurrent
psychosis. Believed to result from a complex interaction
between genetic and environmental factors, schizophrenia is
among the top 10 illnesses in the global burden of disease
(Murray et al. 1996). Considering the paramount importance
of this disorder and the contradicting results of the previous
studies investigating the genetic factors involved in the
pathogenesis of this common psychiatric disease, we con-
ducted this meta-analysis including 68 studies with 15,200
cases and 18,111 controls investigating the association of
four SNPs involved in dopaminergic signalling (rs6277,
rs1799732, rs1800497 and rs1801028) and schizophrenia.
Our meta-analysis has the largest sample size among the
meta-analysis conducted to date on this matter. Nevertheless,
lack of meta-regression analyses was a potential limitation of
this study. Different sources of the control population, var-
ious ethnic backgrounds, differences in the mean age of the
control groups, and variations in gender ratios among the
studies were potential sources of heterogeneity. Overall, our
results indicated that rs1800497 polymorphism shows a
protective effect against schizophrenia. However, no asso-
ciations were found between the other three studied variants
and risk of schizophrenia.
Other meta-analyses have previously investigated the
association between genetic polymorphisms and the risk of
schizophrenia (Glatt et al. 2004; Yao et al. 2015; He et al.
2016). Although our results showing the lack of association
Figure 5. Forest plot of the risk of schizophrenia associated with
rs1801028 under (a) allelic, (b) dominant, and (c) recessive genetic
models.
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of the mentioned SNPs with schizophrenia has largely been
observed in the previous studies, the protective effect of
rs1800497 against schizophrenia is a notable observation.
This SNP which is also known as Taq1A was originally
associated with the DRD2 gene. However, it was later found
to be located on the eighth exon of the ANKK1 gene (Neville
et al. 2004). This polymorphism which leads to an amino-
acid substitution (p. Glu713Lys) in the 11th ankyrin repeat
of the protein is postulated to modify substrate-binding
specificity of the protein (Neville et al. 2004). Our bioin-
formatics analyses were also suggestive of decreased protein
stability and gain of posttranslational modification sites for
ubiquitination and methylation as a result of this polymor-
phism. The wild-type amino-acid in this position, glutamic
acid, has a –COO- group which causes it to have a negative
charge at physiologic pH while lysine has a positive charge.
This substitution can, therefore, disrupt the salt bridges
formed between the wild-type glutamic acid and lysine
amino acids at positions 709 and 747 and therefore affect the
function of the protein through disturbing the interaction
between these domains. However, the structural analysis did
not reveal any significant changes in the protein conforma-
tion as a result of this variant.
The minor allele (i.e. A1, rs1800497(T)) in this poly-
morphism has been found to be associated with decreased
number of dopamine D2 receptor density/availability in the
brain (Pohjalainen et al. 1998). In addition, the A1 allele has
been demonstrated to be associated with increased aromatic
L-amino acid decarboxylase activity in the striatum (Laakso
et al. 2005). This enzyme is the final enzyme in dopamine
biosynthesis and will, therefore, cause increased dopamine
synthesis in those carrying Al allele. In addition, positron
emission tomography (PET) studies have shown that this
allele is associated with decreased mean relative glucose
metabolic rate in dopaminergic human brain regions (Noble
et al. 1997). On the other hand, this allele has been reported
to be associated with alcoholism and anti-social behaviour in
alcohol-dependent individuals (Ponce et al. 2003; Munafo
et al. 2007). Considering the complex nature of
schizophrenia and also the multitude of factors playing a part
in the development of this disorder and the limited amount
of information available about ANKK1, it is not clear if
Taq1A polymorphism exerts its effect on dopaminergic
signalling through affecting the DRD2 gene or ANKK1 itself
directly modulates the dopaminergic signalling. Further
functional studies on this variant could shed light on the role
of this polymorphism in the pathogenesis of neuropsychi-
atric disorders.
Overall, our meta-analysis provides supporting evidence
for the protective effect of rs1800497 (Taq1A) polymor-
phism against schizophrenia. However, further studies with
larger sample sizes, particularly in ethnic populations under-
represented in this study (e.g. African populations) should be
conducted to further investigate this association.
References
Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R.,
Kegeles L. S. et al. 2000 Increased baseline occupancy of D2
receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci.
USA 97, 8104–8109.
Alfimova M. V., Golimbet V. E., Korovaitseva G. I., Aksenova E.
V., Lezheiko T. V., Abramova L. I. et al. 2014 Association of the
COMT and DRD2 genes with the ability of schizophrenia
patients to understand the mental state of other people. Neurosci.
Behav. Physiol. 45, 12–18.
Figure 6. (a) Wild type and (b) mutant ANKK1 protein 3D structures. (c) Magnified view of protein. The protein is depicted in grey and
the side chains of the wild-type and the mutant amino acids are illustrated in green and red, respectively.
59 Page 12 of 16 Parham Habibzadeh et al.
Alfimova M. V., Kondratyev N. V., Tomyshev A. S., Lebedeva I.
S., Lezheiko T. V., Kaleda V. G. et al. 2019 Effects of a GWAS-
supported schizophrenia variant in the DRD2 locus on disease
risk, anhedonia, and prefrontal cortical thickness. J. Mol.
Neurosci. 68, 658–666.
Arab A. H. and Elhawary N. A. 2015 Association between ANKK1
(rs1800497) and LTA (rs909253) genetic variants and risk of
schizophrenia. Biomed. Res. Int. 2015, 821827.
Arinami T., Itokawa M., Enguchi H., Tagaya H., Yano S., Shimizu
H. et al. 1994 Association of dopamine D2 receptor molecular
variant with schizophrenia. Lancet 343, 703–704.
Arinami T., Itokawa M., Aoki J., Shibuya H., Ookubo Y., Iwawaki
A. et al. 1996 Further association study on dopamine D2 receptor
variant S311C in schizophrenia and affective disorders. Am.
J. Med. Genet. 67, 133–138.
Arinami T., Gao M., Hamaguchi H. and Toru M. 1997 A functional
polymorphism in the promoter region of the dopamine D2
receptor gene is associated with schizophrenia. Hum. Mol. Genet.
6, 577–582.
Asherson P., Williams N., Roberts E., McGuffin M. and Owen M.
1994 DRD2 Ser311/Cys311 polymorphism in schizophrenia.
Lancet 343, 1045.
Beaulieu J. M. and Gainetdinov R. R. 2011 The physiology,
signaling, and pharmacology of dopamine receptors. Pharmacol.
Rev. 63, 182–217.
Begg C. B. and Mazumdar M. 1994 Operating characteristics of a
rank correlation test for publication bias. Biometrics 50,
1088–1101.
Behravan J., Hemayatkar M., Toufani H. and Abdollahian E. 2008
Linkage and association of DRD2 gene TaqI polymorphism with
schizophrenia in an Iranian population. Arch. Iranian Med. 11,
252–256.
Betcheva E. T., Mushiroda T., Takahashi A., Kubo M., Karachanak
S. K., Zaharieva I. T. et al. 2009 Case-control association study
of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as
the only susceptibility factor for schizophrenia in the Bulgarian
population. J. Hum. Genet. 54, 98–107.
Breen G., Brown J., Maude S., Fox H., Collier D., Li T. et al. 1999
141 C Del/Ins polymorphism of the dopamine receptor 2 gene is
associated with schizophrenia in a British population. Am.
J. Med. Genet. 88, 407–410.
Campion D., d’Amato T., Bastard C., Laurent C., Guedj F., Jay M.
et al. 1994 Genetic study of dopamine D1, D2, and D4 receptors
in schizophrenia. Psychiatry Res. 51, 215–230.
Cardno A. G. and Gottesman II 2000 Twin studies of schizophre-
nia: from bow-and-arrow concordances to star wars Mx and
functional genomics. Am. J. Med. Genet. 97, 12–17.
Chen C. H., Chien S. H. and Hwu H. G. 1996 No association of
dopamine D2 receptor molecular variant Cys311 and schizophre-
nia in Chinese patients. Am. J. Med. Genet. b. Neuropsychiatr.
Genet. 67, 418–420.
Comings D. E., Comings B. G., Muhleman D., Dietz G.,
Shahbahrami B., Tast D. et al. 1991 The dopamine-D2 receptor
locus as a modifying gene in neuropsychiatric disorders. Jama-J.
Am. Med. Asso. 266, 1793–1800.
Cordeiro Q. and Vallada H. 2014 Association study between the
Taq1A (rs1800497) polymorphism and schizophrenia in a
Brazilian sample. Arquivos De Neuro-Psiquiatria 72, 582–586.
Cordeiro Q., Siqueira-Roberto J., Zung S. and Vallada H. 2009
Association between the DRD2-141C insertion/deletion poly-
morphism and schizophrenia. Arquivos De Neuro-Psiquiatria 67,
191–194.
Crawford F., Hoyne J., Cai X. G., Osborne A., Poston D., Zaglul J.
et al. 1996 Dopamine DRD2/Cys311 is not associated with
chronic schizophrenia. Am. J. Med. Genet. 67, 483–484.
Dollfus S., Campion D., Vasse T., Preterre P., Laurent C., d’Amato
T. et al. 1996 Association study between dopamine D1, D2, D3,
and D4 receptor genes and schizophrenia defined by several
diagnostic systems. Biol. Psychiat. 40, 419–421.
Dubertret C., Gorwood P., Gouya L., Deybach J. C. and Ades J.
2001 Association and excess of transmission of a DRD2
haplotype in a sample of French schizophrenic patients.
Schizophrenia Res. 49, 203–212.
Dubertret C., GouyaL.,HanounN.,Deybach J.C.,Ades J., HamonM.
et al. 2004 The 3 ’ region of the DRD2 gene is involved in genetic
susceptibility to schizophrenia. Schizophrenia Res. 67,
75–85.
Dubertret C., Bardel C., Ramoz N., Martin P. M., Deybach J. C.,
Ades J. et al. 2010 A genetic schizophrenia-susceptibility region
located between the ANKK1 and DRD2 genes. Prog. Neuro-
Psychopharmacol. Biol. Psychiat. 34, 492–499.
Egger M., Davey Smith G., Schneider M. and Minder C. 1997 Bias
in meta-analysis detected by a simple, graphical test. BMJ 315,
629–634.
Fan H., Zhang F. Q., Xu Y., Huang X. Z., Sun G. X., Song Y. Q.
et al. 2010 An association study of DRD2 gene polymorphisms
with schizophrenia in a Chinese Han population. Neurosci. Lett.
477, 53–56.
Fujiwara Y., Yamaguchi K., Tanaka Y., Tomita H., Shiro Y.,
Kashihara K. et al. 1997 Polymorphism of dopamine receptors
and transporter genes in neuropsychiatric diseases. Eur. Neurol.
38 (suppl 1), 6–10.
Funahashi Y., Yoshino Y., Yamazaki K., Ozaki Y., Mori Y., Mori T.
et al. 2019 Analysis of methylation and -141C Ins/Del
polymorphisms of the dopamine receptor D2 gene in patients
with schizophrenia. Psychiatr. Res. 278, 135–140.
Gejman P. V., Ram A., Gelernter J., Friedman E., Cao Q., Pickar D.
et al. 1994 No structural mutation in the dopamine D2 receptor
gene in alcoholism or schizophrenia: Analysis using denaturing
gradient gel electrophoresis. J. Am. Med. Asso. 271, 204–208.
Glatt S. J. and Jonsson E. G. 2006 The Cys allele of the DRD2
Ser311Cys polymorphism has a dominant effect on risk for
schizophrenia: evidence from fixed- and random-effects meta-
analyses. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B,
149–154.
Glatt S. J., Faraone S. V. and Tsuang M. T. 2004 DRD2 -141C
insertion/deletion polymorphism is not associated with
schizophrenia: results of a meta-analysis. Am. J. Med. Genet.
B Neuropsychiatr. Genet. 128B, 21–23.
Gupta M., Chauhan C., Bhatnagar P., Gupta S., Grover S., Singh P.
K. et al. 2009 Genetic susceptibility to Schizophrenia: Role of
dopaminergic pathway gene polymorphisms. Pharmacoge-
nomics 10, 277–291.
Han J., Li Y. and Wang X. 2017 Potential link between genetic
polymorphisms of catechol-O-methyltransferase and dopamine
receptors and treatment efficacy of risperidone on schizophrenia.
Neuropsychiatr. Dis. Treat. 13, 2935–2943.
Hanninen K., Katila H., KampmanO., Anttila S., Illi A., Rontu R. et al.
2006Associationbetween theC957Tpolymorphismof thedopamine
D2 receptor gene and schizophrenia. Neurosci. Lett. 407,
195–198.
Harano M. 1997 Ser-311-Cys polymorphism of the dopamine D2
receptor gene and schizophrenia–an analysis of schizophrenic
patients in Fukuoka. Kurume Med. J. 44, 201–208.
Hattori M., Nanko S., Dai X. Y., Fukuda R. and Kazamatsuri H.
1994 Mismatch PCR RFLP detection of DRD2 SER311CYS
polymorphism and schizophrenia. Biochem. Biophys. Res. Com-
mun. 202, 757–763.
He H., Wu H., Yang L., Gao F., Fan Y., Feng J. et al. 2016
Associations between dopamine D2 receptor gene polymor-
phisms and schizophrenia risk: a PRISMA compliant meta-
analysis. Neuropsychiatr. Dis. Treat. 12, 3129–3144.
Himei A., Koh J., Sakai J., Inada Y., Akabame K. and Yoneda H.
2002 The influence on the schizophrenic symptoms by the
Dopaminergic signalling polymorphisms and schizophrenia Page 13 of 16 59
DRD2Ser/Cys311 and-141C Ins/Del polymorphisms. Psychiatr.
Clini. Neurosci. 56, 97–102.
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